Prof. Erika Lietzan

Professor Lietzan Files Amicus Brief with U.S. Supreme Court in Patent Case

March 24th, 2017

Professor Lietzan recently filed an amicus brief in the United States Supreme Court, in a closely-watched case involving patent litigation under the Biologics Price Competition and Innovation Act (BPCIA). The appellate court concluded that biosimilar applicants may

Read More

Professor Lietzan Quoted on Selection of FDA Commissioner

March 23rd, 2017

Professor Erika Lietzan was recently quoted in BuzzFeed News regarding President Donald Trump’s selection of Dr. Scott Gottlieb to be the next commissioner of the U.S. Food & Drug Administration. Dr. Gottlieb was deputy commissioner under President

Read More

Citizen Petitions at the FDA: Professor Lietzan Interviewed by The Atlantic

March 20th, 2017

Professor Erika Lietzan was recently interviewed by a reporter for The Atlantic in connection with the use of “citizen petitions” at the U.S. Food & Drug Administration (FDA). A recent article in the New England Journal of

Read More

Professor Lietzan Quoted on “Right to Try” Legislation

March 17th, 2017

Professor Erika Lietzan was recently quoted in numerous papers around the country in connection with possible federal “right to try” legislation. Broadly speaking, the purpose of state “right to try” laws is to make it possible for

Read More

Professor Lietzan Discusses Executive Order’s Possible Impact on Food and Drug Administration

February 1st, 2017

Professor Erika Lietzan was quoted at length today in an article published by the Regulatory Affairs Professional Society (RAPS) about the impact of President Trump’s January 30 “two-for-one” executive order on the U.S. Food and Drug Administration

Read More